|Videos|March 31, 2022

Dr. David Law on being awarded Medtronic’s Center of Excellence designation

Author(s)Urology Times staff

“It's just very exciting to be a part of a company that's made such an improvement in patients' lives,” says David W. Law, DO.

In this video, David W. Law, DO, discusses being awarded Medtronic’s Center of Excellence Designation for InterStim, a sacral nerve modulation therapy for treatment of overactive bladder. Law is the chief of surgery at Oakwood Southshore Medical Center in Trenton, Michigan, and clinical professor in the department of urology at the Michigan State University Medical School in East Lansing.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com

Paying tribute to Sakti Das, MD

ByGopal H. Badlani, MD

January 3rd 2025

Expert Opinion: We cannot continue to ignore the problem of physician mental distress

ByRussell Libby, MD

April 22nd 2022

Dr. Polina Reyblat discusses her SUFU presentation on transgender and non-binary health care

ByUrology Times staff

March 31st 2022

Dr. Vince provides recommendations for future DEI initiatives in the AUA

ByUrology Times staff

March 31st 2022

Dr. Pruthi discusses the issue of mental health stigma and why physicians are reluctant to seek care

March 30th 2022

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC